GLUE

Monte Rosa Therapeutics, Inc. GLUE

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,461 of 2,925

Why it scores 31Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$8.97M

Quarter to Jun 30

Net income

$-43.40M

Quarter to Jun 30

Free cash flow

$-48.84M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.24B total
PRICE T ROWE ASSOCIATES INC /MD/
$214.44M+31.9%
NEA Management Company, LLC
$186.15M0.0%
BlackRock, Inc.
$165.60M+21.4%
TCG Crossover Management, LLC
$111.86M0.0%
Vestal Point Capital, LP
$111.32M+27.7%
BVF INC/IL
$107.95M0.0%
BAKER BROS. ADVISORS LP
$105.17M0.0%
STATE STREET CORP
$90.30M+11.3%
SUVRETTA CAPITAL MANAGEMENT, LLC
$85.90M-16.0%
VANGUARD CAPITAL MANAGEMENT LLC
$82.59M+10.1%
Versant Venture Management, LLC
$76.97M0.0%
BRAIDWELL LP
$59.33M-23.5%
GEODE CAPITAL MANAGEMENT, LLC
$45.12M+21.0%
AMERICAN CENTURY COMPANIES INC
$39.27M-42.2%
MARSHALL WACE, LLP
$38.57M+11.2%
Aisling Capital Management LP
$37.65M0.0%
Bellevue Group AG
$28.80M-4.8%
DIMENSIONAL FUND ADVISORS LP
$28.49M+13.1%
MPM BioImpact LLC
$28.10M-1.3%
SILVERARC CAPITAL MANAGEMENT, LLC
$26.82M-44.6%
Jupiter Topco LLC
$25.97M--
Frazier Life Sciences Management, L.P.
$24.20M0.0%
GOLDMAN SACHS GROUP INC
$24.16M-0.3%
Woodline Partners LP
$23.30M+1192.5%
FMR LLC
$22.61M-8.8%
See all 193 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GLUE

Earnings Per Share

13fpro.ai/company/GLUE

Loading ratio trend…

GLUE key financials by period

Reported revenue, net income and operating margin by fiscal year, from Monte Rosa Therapeutics, Inc.'s annual filings on SEC EDGAR.

Monte Rosa Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$123.7M$-38.6M-43.8%
FY 2024$75.6M$-72.7M-107.3%
Source: GLUE filings on SEC EDGAR →

About Monte Rosa Therapeutics, Inc. (GLUE): stock profile, AI score and financials

Monte Rosa Therapeutics, Inc. (GLUE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GLUE at 30.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,461 of 2,925 stocks — the bottom half of the AI-ranked universe. GLUE scores in the top quartile across revenue growth (99.4). Areas of concern include profitability (3.4) and revenue scale (5.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Monte Rosa Therapeutics, Inc. reports quarterly revenue of $9.0M, net income of $-43.4M, free cash flow of $-48.8M. Top institutional holders of GLUE by reported 13-F value include PRICE T ROWE ASSOCIATES, NEA Management Company, BlackRock, based on the most recent SEC filings. GLUE trades on the Nasdaq exchange and files with the SEC under CIK 1826457. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Monte Rosa Therapeutics, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1826457 →